Europe Meningococcal Vaccines Market Size & Outlook
Europe meningococcal vaccines market, 2018-2030 (US$M)
Related Markets
Europe meningococcal vaccines market highlights
- The Europe meningococcal vaccines market generated a revenue of USD 790.4 million in 2021.
- The market is expected to grow at a CAGR of 6.6% from 2022 to 2030.
- In terms of segment, bivalent was the largest revenue generating type in 2021.
- Quadrivalent is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Russia is expected to register the highest CAGR from 2022 to 2030.
Europe data book summary
| Market revenue in 2021 | USD 790.4 million |
| Market revenue in 2030 | USD 1,406.7 million |
| Growth rate | 6.6% (CAGR from 2021 to 2030) |
| Largest segment | Bivalent |
| Fastest growing segment | Quadrivalent |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bivalent, Quadrivalent |
| Key market players worldwide | Pfizer Inc, Sanofi SA, GSK PLC, Merck & Co Inc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology |
Other key industry trends
- In terms of revenue, Europe region accounted for 27.5% of the global meningococcal vaccines market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- MEA is the fastest growing regional market and is projected to reach USD 141.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Meningococcal Vaccines Market Scope
Meningococcal Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe meningococcal vaccines market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to meningococcal vaccines market will help companies and investors design strategic landscapes.
Bivalent was the largest segment with a revenue share of 62.9% in 2021. Horizon Databook has segmented the Europe meningococcal vaccines market based on bivalent, quadrivalent covering the revenue growth of each sub-segment from 2018 to 2030.
The presence of sophisticated technology, well-established research infrastructure, and strong market players in Europe regions is responsible for market growth. Moreover, rising awareness about meningococcal vaccine coupled with increasing prevalence of this disease is expected to boost market growth.
Approval of new vaccines that are affordable and have similar immune response & reduced schedule is expected to propel market growth. For instance, in November 2020, the European Commission approved Men Quadfi for individual aged 12 months and above against serogroups A, C, W, & Y.
Moreover, in June 2018, GlaxoSmithKline plc received approval from European Commission for Bexsero. Thus, increasing approval of novel products in the region is expected to drive market growth over the forecast period.
Reasons to subscribe to Europe meningococcal vaccines market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe meningococcal vaccines market databook
-
Our clientele includes a mix of meningococcal vaccines market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe meningococcal vaccines market , including forecasts for subscribers. This continent databook contains high-level insights into Europe meningococcal vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe meningococcal vaccines market size, by country, 2018-2030 (US$M)
Europe Meningococcal Vaccines Market Outlook Share, 2021 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
